Benefit–Risk Assessment of Diacerein in the Treatment of Osteoarthritis

@article{Panova2015BenefitRiskAO,
  title={Benefit–Risk Assessment of Diacerein in the Treatment of Osteoarthritis},
  author={Elena E. Panova and Graeme Jones},
  journal={Drug Safety},
  year={2015},
  volume={38},
  pages={245-252}
}
Osteoarthritis (OA) is the leading musculoskeletal cause of disability. Despite this, there is no consensus on the precise definition of OA and what is the best treatment to improve symptoms and slow disease progression. Current pharmacological treatments include analgesics, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX) inhibitors. None of those treatments are disease-modifying agents that target the core pathological processes in OA. Diacerein, a semi-synthetic… 
Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
TLDR
The ESCEO concludes that the benefit–risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.
Investigational drugs for the treatment of osteoarthritis, an update on recent developments
TLDR
There is no miracle drug that can be used for all OA patients’; treatment and disease stage is crucial for the effectiveness of drugs, so the development of investigational drugs targeting at symptoms and disease progression of OA is expedited.
Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial
TLDR
These preliminary results show the potential benefits of diacerein on pain, joint function, and disease activity in MTX-IR RA patients and a good safety profile of diACErein has been observed when it was administered as add-on therapy to methotrexate in patients with rheumatoid arthritis.
Diacerein, its beneficial impact on chondrocytes and notable new clinical applications
TLDR
It has been reviewed that apart from the risk of diarrhea on long-term administration of DCN, various clinical studies has also shown its modest benefits in treatment of various pathological conditions and DCN is emerging as a new and potentially safe derivative with maximum therapeutic efficacies and minimum side effects which can results in improving the living status of patients suffering from various inflammatory diseases.
A COMPARATIVE STUDY ON THE SAFETY AND EFFECTIVENESS OF GLUCOSAMINE-DIACEREIN AND UNIVESTIN – CHONDROITIN IN KNEE OSTEOARTHRITIC PATIENTS IN A TERTIARY CARE HOSPITAL
TLDR
For Grade 1 patients both drugs were equally effective, but for Grade 2 Patients diacerein-glucosamine combination therapy shows more benefit than univestin-chondroitin, however, semi-synthetic drug combination showed more safety profile than synthetic drug combination in the short term treatment of knee osteoarthritis.
Current status and future prospects for disease modification in osteoarthritis
TLDR
A comprehensive review is performed to discuss the current status of disease-modifying therapies in OA and appraise the potentials of emerging novel agents.
The Efficacy and Safety of Disease-Modifying Osteoarthritis Drugs for Knee and Hip Osteoarthritis—a Systematic Review and Network Meta-Analysis
TLDR
None of the 12 classes of drugs appears to have long-term clinically significant benefit on structure and symptoms, though both glucosamine and chondroitin had favorable safety profiles and Strontium improved structure, and vitamin D improved symptoms.
Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial
TLDR
Diacerein reduced mean HbA1c levels, with peak of effect at the 24th week of treatment, and may be indicated as adjunct treatment in patients with type 2 diabetes, particularly in those with osteoarthritis.
An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis.
TLDR
Diacerein was non-inferior to celecoxib in reducing knee OA pain and improving physical function and demonstrated a good safety profile.
...
1
2
3
...

References

SHOWING 1-10 OF 13 REFERENCES
Diacerein for osteoarthritis.
TLDR
Low-quality evidence from six trials indicates that diacerein has a small beneficial effect on overall pain, and this updated review now includes 10 trials, totalling 2,210 participants.
Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group.
TLDR
Diacerein, a drug for the treatment of OA, was shown to be an effective treatment for symptoms in patients with knee OA and the optimal daily dosage is 100 mg/day (50 mg twice daily).
Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip.
TLDR
It is confirmed that the demonstration of a structure-modifying effect in hip OA is feasible, and shows, for the first time, that treatment with diacerein for 3 years has a significant structure- modifying effect as compared with placebo, coupled with a good safety profile.
Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis.
TLDR
A weak but statistically significant structural deterioration occurred over 1 year, together with clinically relevant symptomatic improvement in patients receiving oral drug and iterative IA injections.
The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period.
TLDR
The results show that diacerein is safe and effective for the treatment of knee OA and has a long carryover effect.
Sources of pain in osteoarthritis: implications for therapy
TLDR
Improvements in basic science have greatly enhanced the understanding that osteoarthritis is an umbrella term for a number of pathways leading to very similar pain and structural outcomes; these outcomes are leading to lesion-specific therapies, which indicate the importance of trying to pinpoint causes of pain in the individual.
OARSI-FDA initiative: defining the disease state of osteoarthritis.
Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults.
...
1
2
...